History

The Lindner Research Center strives to identify the most promising therapies and provide them to patients. The center works hard to establish satisfying relationships with patients and referring physicians to ensure the best outcomes.

Center History

In 1985, Dean Kereiakes, M.D. partnered with Charles Abbottsmith, M.D. and began participating in formal research trials at The Christ Hospital.The first studies administered early thrombolytic agents for the treatment of acute myocardial infarction. In 1988, Dr. Kereiakes received the opportunity to participate in a large percutaneous transluminal coronary angioplasty/restenosis trial that demanded a formal staff for execution and management. The Christ Hospital Cardiovascular Research Center was opened to provide resources for this study. Dr. Kereiakes was named medical director and Charles Abbottsmith, M.D., was appointed associate medical director. The primary goal of this new department was to make new technology and therapies for cardiovascular diseases available and to enhance the quality of cardiovascular care in our region.

In 1996, the center’s name was changed to The Carl & Edyth Lindner Center for Clinical Cardiovascular Research, to honor the couple who have contributed so much to The Christ Hospital and the community. Trials grew in number and scope. In 1999, the Center became an independent and formed two separate organizations: The Lindner Clinical Trial Center, an S-corporation that executed the then more than 120 trials on an ongoing basis, and the Carl & Edyth Lindner Center for Research and Education, a 501c3 that provided education to both consumers and physicians through forums, publications and formal hands on and observational preceptorships. By 2000, the Center was also conducting multi-specialty medical research trials, in areas such as oncology, dementia, orthopedic, gastrointestinal, infectious disease and anesthesia. 

The Lindner Research Center continued to grow through the years in number of trials and the complexity of the protocols. Major focuses of trials were in the areas of percutaneous coronary intervention, antiplatelet therapies and new devices for coronary intervention. Again, many more physicians were becoming involved in these studies as participating investigators. 

In 2009, the Center formally re-joined The Christ Hospital and continues in name as The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, functioning with both 120 active clinical trials, and production of more than 45 publications in the past year, as well as educational forums for both physicians and consumers throughout the year. 

In 2010, The Christ Hospital Human Research Protection Program (HRPP) received full accreditation from The Association for the Accreditation of Human Research Protection Programs (AAHRPP). The Christ Hospital is one of 214 organizations worldwide to achieve this status. The HRPP includes an Institutional Review Board (IRB) which must approve all research, as well as clinical investigators, nursing and hospital departments.

Through these trials four first-in-man and five first-in-the-U.S. procedures have been performed at The Christ Hospital. Additionally, the center has experienced nine successful Food and Drug Administration audits ( no formal recommendations), chosen due to high volume enrollment  and high profile trials. The Lindner Research Center has a reputation of providing fast project start up, with more than 50 percent of trials being the first site initiated, as well as  strong patient enrollment and high quality efficient data reporting. 

 


  • Tryton side branch stent (first patient in the nation)

    Laptop Trial (first patient in Cincinnati)

    Prompt Trial (first patient worldwide)

    2011
  • Crosser (first patient in the nation)

    2010
  • SPIRIT PRIME

    2009
  • Chronicle ICD / Reduce-hf (first in man)

    2006
  • COSTAR II Trial

    SPIRIT III

    2005
  • Cholesterol / Diabetes Treatment: CETP

    HDL-raising medicine

    2004
  • Branch Vessel Stents (first in USA)

    Myoblast Cell Therapy Transplant

    Distal Embolic Protection During Angioplasty: Interceptor

    Microvena Filter MASTER

    2003
  • Retevase (rPA) Angiogenesis Gene Therapy with Adenoviral

    2002
  • Drug Eluting Stents T-Wave Alternans (TWA)

    COBALT - Chromium Alloy Stents (first vision stent in man)

    Distal Embolic Protection During Angioplasty: EPI Filterwire

    Cholesterol / Diabetes Treatment: HDL - cholesterol vaccine

    2001
  • Enhanced External Counterpulsation (EECP)

    Alcohol Septal Ablation for HOCM/IHSS

    Photodynamic Laser Therapy (first in man)

    Distal Embolic Protection During Angioplasty: Percusurge

    Abdominal Aortic Aneurysm Stent Graft

    2000
  • Angiogenesis with FGF

    1999
  • IntraCoronary Radiation: Beta Covered Stents

    1998
  • IntraCoronary Radiation: Gamma

    Laser Pacemaker Lead Extraction

    Angiogenesis with VEGF

    1997
  • Retevase (rPA)

    Oral Platelet Glycoprotein IIb/IIIa Inhibitors

    1995
  • Tirofiban (MK383)

    1993
  • Integrelin

    1992
  • Excimer Laser Rotational Atherectomy

    1991
  • ReoPro First Coronary Stents (Gianturco-Roubin I)

    1990
  • Directional Atherectomy Extraction

    1989
  • Tissue Plasminogen Activator (tPA)

    1986
  • Balloon Angioplasty

    1980

Learn more about:

Awards/Certifications

The Christ Hospital has been recognized for its achievements.

Learn more
Annual Report

The Christ Hospital Cardiovascular Outcomes 2011.

Learn more (PDF)